Beyond the Headlines: What Compliance Professionals Should Learn from the Advanced Pathology Settlement

The recent $30 million settlement involving Advanced Pathology Solutions (APS) is being reported as another kickback case. While that's true, focusing only on the Anti-Kickback Statute misses the bigger compliance lesson.

This case provides a valuable roadmap for understanding how healthcare fraud schemes are often operationalized and why compliance professionals must look beyond individual transactions to examine the underlying business model.

The Business Model That Raised Concerns

According to the government's allegations, APS developed a model built around what were referred to as "lean labs."

APS established and managed limited-purpose laboratories inside gastroenterology practices across the country. These laboratories performed certain specimen preparation functions, such as preparing and staining biopsy slides.

The gastroenterology practices could then bill for those technical services.

In exchange, the practices allegedly agreed to send all of their pathology interpretation work exclusively to APS.

On paper, each arrangement may have appeared operationally efficient.

In practice, however, the government alleged that the laboratories and related benefits provided by APS constituted remuneration designed to influence referral decisions.

This is an important compliance lesson.

The highest-risk arrangements are often not direct cash payments. Instead, they may involve:

• Free or discounted services

• Staffing support

• Equipment

• Operational infrastructure

• Management services

• Revenue-generating opportunities

Whenever an organization is providing something of value to a referral source, compliance should be asking a simple question:

Would this arrangement still exist if no referrals were involved?

How the Testing Scheme Allegedly Worked

The second component of the case involved medical necessity. The government alleged that APS directed laboratory personnel to automatically perform certain special stains before a pathologist reviewed the initial routine slide.

Under normal clinical practice, a pathologist reviews the initial specimen and determines whether additional testing is necessary. According to the allegations, APS reversed that process. Rather than allowing the physician's clinical judgment to drive testing decisions, additional testing was allegedly triggered automatically through standardized protocols.

The government further alleged that APS frequently performed additional confirmatory testing after receiving specimens from the lean labs, even when such testing was not medically necessary.

From a compliance perspective, this is a critical distinction. Standardization can improve quality and efficiency. However, standardization becomes risky when it replaces individualized clinical decision-making.

Compliance Red Flags Hidden in Plain Sight

Several warning signs emerge from the government's allegations:

Red Flag #1: Referral Exclusivity

The gastroenterology practices allegedly agreed to send all pathology work to APS.

Whenever a business arrangement results in exclusive referral patterns, compliance should evaluate whether financial incentives may be influencing provider decision-making.

Red Flag #2: Revenue Generation for Referral Sources

The lean lab model allegedly allowed physician practices to generate revenue through technical laboratory services.

Whenever a referral source benefits financially from a relationship, organizations should carefully evaluate Anti-Kickback Statute and Stark Law implications.

Red Flag #3: Automatic Clinical Protocols

Protocols that automatically trigger additional testing should receive heightened scrutiny.

Compliance and clinical leadership should ensure that standing protocols are evidence-based, medically necessary, and appropriately documented.

Red Flag #4: Volume-Based Compensation

The government also alleged that APS paid a marketing representative a commission equal to 4% of collections generated from referred epidermal nerve fiber density testing.

Volume-based compensation tied directly to federal healthcare business remains one of the most recognizable Anti-Kickback Statute risk areas.

Whenever compensation increases based on the volume or value of referrals, organizations should proceed with extreme caution.

What Compliance Officers Should Be Asking

Cases like APS demonstrate why compliance reviews cannot focus solely on contracts.

Organizations should periodically ask:

• Why are referral sources choosing us?

• What value are we providing beyond clinical services?

• Are any referral sources receiving operational or financial benefits?

• Are testing protocols driven by physician judgment or by revenue opportunities?

• Are we monitoring utilization trends for outlier ordering patterns?

• Could we clearly explain and defend this arrangement to a government investigator?

If the answer to that last question is uncomfortable, further review is warranted.

The Real Takeaway

The APS settlement serves as a reminder that healthcare fraud often begins with a business model that appears innovative, efficient, or mutually beneficial. The compliance risk emerges when financial incentives begin influencing referral decisions or clinical judgment.

For compliance professionals, the most important question is not whether an arrangement technically complies with a contract. The question is whether the arrangement creates incentives that could distort independent medical decision-making.

When financial relationships drive referrals and protocols drive unnecessary testing, the resulting claims may quickly become False Claims Act exposure.